3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
fludarabine
10
Specimen Handling
8
Cytarabine
8
Cyclophosphamide
8
Biopsy
8
fludarabine phosphate
7
Whole-Body Irradiation
7
venetoclax
6
Injections
6
Busulfan
6
Azacitidine
6
Mycophenolic Acid
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
decitabine and cedazuridine drug combination
4
X-Rays
4
Tacrolimus
4
Stem Cell Transplantation
4
Cyclosporine
4
CPX-351
4
Peripheral Blood Stem Cell Transplantation
3
Magnetic Resonance Spectroscopy
3
Idarubicin
3
Decitabine
3
treosulfan
2
ruxolitinib
2
luspatercept
2
ivosidenib
2
gilteritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
posaconazole
×
30 days
×
Clear all
NCT07155226
2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2
Recruiting
84 enrolled